Estradiol/testosterone transdermal - Procter & Gamble/Watson

Drug Profile

Estradiol/testosterone transdermal - Procter & Gamble/Watson

Alternative Names: Testosterone/estradiol transdermal - Watson

Latest Information Update: 11 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Watson Laboratories
  • Class Estradiol congeners; Estrenes; Hormonal replacements; Testosterone congeners
  • Mechanism of Action Estrogen receptor agonists; Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Female sexual dysfunction; Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 27 Jun 2006 No development reported - Phase-I for Female sexual dysfunction in USA (Transdermal)
  • 27 Jun 2006 No development reported - Phase-I for Menopausal syndrome in USA (Transdermal)
  • 27 Jun 2006 No development reported - Phase-I for Postmenopausal osteoporosis in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top